Synapse

← Lung Cancer Targets and Therapy

Papers in Lung Cancer Targets and Therapy

Page 2 · newest first

  1. Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping MutationLung Cancer Targets and Therapy · 2022
  2. Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant OsimertinibLung Cancer Targets and Therapy · 2022
  3. An Update on Emerging Therapeutic Options for Malignant Pleural MesotheliomaLung Cancer Targets and Therapy · 2022
  4. Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2021
  5. The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung CancersLung Cancer Targets and Therapy · 2021
  6. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2021
  7. Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2021
  8. Targeting AXL in NSCLCLung Cancer Targets and Therapy · 2021
  9. An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung CancerLung Cancer Targets and Therapy · 2021
  10. Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion MutationsLung Cancer Targets and Therapy · 2021
  11. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2021
  12. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesLung Cancer Targets and Therapy · 2021
  13. Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on CapmatinibLung Cancer Targets and Therapy · 2021
  14. Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK SignalingLung Cancer Targets and Therapy · 2021
  15. Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive StudyLung Cancer Targets and Therapy · 2020
  16. A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their ToxicityLung Cancer Targets and Therapy · 2020
  17. Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung CancerLung Cancer Targets and Therapy · 2020
  18. Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-MutationsLung Cancer Targets and Therapy · 2020
  19. Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the LiteratureLung Cancer Targets and Therapy · 2020
  20. Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2020
  21. Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma PatientsLung Cancer Targets and Therapy · 2020
  22. The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung CancerLung Cancer Targets and Therapy · 2020
  23. Approaches to Tumor Classification in Pulmonary Sarcomatoid CarcinomaLung Cancer Targets and Therapy · 2019
  24. Landscape on CT screening for lung cancer in AsiaLung Cancer Targets and Therapy · 2019
  25. Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkersLung Cancer Targets and Therapy · 2019
  26. Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patientsLung Cancer Targets and Therapy · 2019
  27. Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancerLung Cancer Targets and Therapy · 2019
  28. Pain management in patients with malignant mesothelioma: challenges and solutionsLung Cancer Targets and Therapy · 2019
  29. Targeting RET-rearranged non-small-cell lung cancer: future prospectsLung Cancer Targets and Therapy · 2019
  30. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancerLung Cancer Targets and Therapy · 2019
  31. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysisLung Cancer Targets and Therapy · 2019
  32. Silicosis and lung cancer: current perspectivesLung Cancer Targets and Therapy · 2018
  33. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformationLung Cancer Targets and Therapy · 2018
  34. 1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRTLung Cancer Targets and Therapy · 2018
  35. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patientsLung Cancer Targets and Therapy · 2018
  36. Role and inhibition of GLI1 protein in cancerLung Cancer Targets and Therapy · 2018
  37. Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectivesLung Cancer Targets and Therapy · 2018
  38. Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancerLung Cancer Targets and Therapy · 2018
  39. Bevacizumab in the treatment of NSCLC: patient selection and perspectivesLung Cancer Targets and Therapy · 2017
  40. Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literatureLung Cancer Targets and Therapy · 2017
  41. Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancerLung Cancer Targets and Therapy · 2017
  42. Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment responseLung Cancer Targets and Therapy · 2017
  43. 65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancerLung Cancer Targets and Therapy · 2017
  44. EGFR T790M: revealing the secrets of a gatekeeperLung Cancer Targets and Therapy · 2017
  45. Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in JapanLung Cancer Targets and Therapy · 2017
  46. Prognostic value of soluble major histocompatibility complex class I polypeptide-related sequence A in non-small-cell lung cancer – significance and developmentLung Cancer Targets and Therapy · 2017
  47. New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancerLung Cancer Targets and Therapy · 2017
  48. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyLung Cancer Targets and Therapy · 2017
  49. Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challengesLung Cancer Targets and Therapy · 2017
  50. Proton beam therapy in non-small cell lung cancer: state of the artLung Cancer Targets and Therapy · 2017